**Comparison of sofosbuvir, ribavirin plus peg-interferon-α treatment with**

**sofosbuvir plus ribavirin alone in patients with chronic Hepatitis C**

Zamir Butt1, Syed Muhammad Ali Shah2, Syed Usama Talat3, Muhammad Ajmal3, Irfan Younis1, Muhammad Afzal4

**ABSTRACT**

**Objective:** To compare the efficacy of weekly Peg-interferon-α, weight based ribavirin and sofosbuvir daily for 12 weeks with weight based ribavirin and sofosbuvir daily for 24 weeks in patients with genotype 3a chronic hepatitis C patients.

**Study Design:** Cross-sectional analytical comparative study

**Place and Duration:** Department of Medicine,Aziz Bhatti Shaheed Teaching Hospital Gujrat from November 2015 to July 2017

**Methodology:** Patients with chronic hepatitis C genotype 3 infection were divided in two equal groups. Group A included patients treated with Peg-interferon-α weekly, weight based ribavirin and sofosbuvir daily for 12 weeks and group B included patients treated with weight-based ribavirin and sofosbuvir daily for 24 weeks.

**Results:** Each group contained 107(N) patients. Mean age in group A was 42.22+10.66 years compared to 49.66+10.51 years in group B. Early virological response (EVR) was achieved by 98.13% patients in group A compared to 97.2% in group B. End treatment response (ETR) rates were similar in both groups as EVR rates. Sustained virological response at 24 weeks (SVR24) was achieved by 94% patients in group A compared to 90% in group B. Binary logistic regression analysis showed no association of treatment history and presence of cirrhosis with either of EVR, ETR or SVR24 (p>0.05). Significant difference in treatment response with either regimen was not noted.

**Conclusion:** Dual and triple therapy regimens are equally effective in treating chronic hepatitis C genotype 3 patients.

## Keywords: Peg-interferon-α, Sofosbuvir, HCV, Genotype 3, Hepatitis C, Ribavirin,

**How to Cite This:**

Butt Z, ShahSMA, TalatSU, AjmalM, YounisI, Afzal M. Comparison of sofosbuvir, ribavirin plus peg-interferon-α treatment with sofosbuvir plus ribavirin alone in patients with chronic Hepatitis C.Isra Med J. 2019; 11(6):439-443.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.